Business, energy, technology, markets and global industry news from Business News Today

The University of Texas MD Anderson Cancer Center

PharmaDeviceNews The University of Texas MD Anderson Cancer Center
A representative image illustrating Oncolytics Biotech’s pelareorep colorectal cancer research as FDA feedback outlines a potential accelerated approval path in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer.
Pharma & Biotech

Pelareorep gets clearer FDA path toward accelerated approval in RAS-mutant colorectal cancer

FDA feedback could let pelareorep move directly into a pivotal colorectal cancer expansion if randomized REO 033 data support accelerated approval.

Read More